Clinical trials: insulin glargine
Type 1 Diabetes Mellitus
Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus
Primary Objective: To compare the pharmacokinetic (PK) characteristics of single doses of insulin glargine given as U200 and U500 with those of a single dose (SD) of Lantus® U100 in a euglycemic clamp setting in subjects with…
- Trial name
- NCT02201199
- Testing
- insulin glargine U200 HOE901, insulin glargine U500 HOE901, insulin glargine U100 HOE901
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in HbA1c from baseline to endpoint (scheduled month 6) in adult participants with type 2 diabetes mellitus Secondary…
- Trial name
- EDITION I (NCT01499082)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 807 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA
The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.
- Trial name
- NCT00732524
- Testing
- Glipizide, Glipizide and Glargine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cook County Health
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00184613
- Testing
- pump, insulin glargine, insulin aspart
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the pharmacodynamic properties of two different doses of a new insulin glargine formulation with 0.4 U/kg Lantus® Secondary Objective: To compare the pharmacokinetic properties of two different doses…
- Trial name
- NCT01493115
- Testing
- Insulin glargine HOE901, Insulin glargine - New formulation HOE901
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese patients with type 1 diabetes…
- Trial name
- EDITION JP I (NCT01689129)
- Testing
- Insulin glargine new formulation (HOE901), Insulin glargine (HOE901) (Lantus)
- Where
- 22 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin…
- Trial name
- NCT00653341
- Testing
- insulin glargine, NPH human insulin
- Where
- 2 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- Sanofi
Pemphigus Vulgaris, Skin Erosion
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
This study investigates the efficacy of topical insulin in promoting healing of pemphigus vulgaris erosions. Twenty patients with pemphigus vulgaris were enrolled, each contributing three comparable lesions randomly allocated to…
- Conditions
- Pemphigus Vulgaris, Skin Erosion, Autoimmune Blistering Disease
- Trial name
- NCT07461103
- Testing
- insulin glargine, human insulin, 0.9% Normal Saline
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Diabetes, Diabetes Mellitus, Type 1
The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins
This trial is conducted in Europe. The aim of this research is to assess the impact of three basal (long-acting) insulin treatments on blood glucose levels in people with type 1 diabetes when performing physical exercise.
- Trial name
- NCT00313742
- Testing
- insulin detemir, insulin glargine, insulin NPH
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
It has been shown that individuals with type 2 diabetes have higher blood sugar throughout the night than individuals without type 2 diabetes.
- Trial name
- NCT05098470
- Testing
- Metformin, Insulin Glargine, Dorzagliatin
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Diabetes
Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics
Over the past 40 years, new types of insulins have been marketed to mirror the effect of endogenous insulin. With the existing long-acting insulin product patents expiring and the FDA approval of new biosimilar and innovator…
- Trial name
- NCT02922179
- Testing
- Long- and intermediate- acting insulins
- Volunteers
- 103,951 people
- Sponsor
- Biologics & Biosimilars Collective Intelligence Consortium
Healthy, Diabetes
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a range of single doses of subcutaneous insulin 338.
- Conditions
- Healthy, Diabetes, Diabetes Mellitus, Type 1
- Trial name
- NCT02220296
- Testing
- Insulin 338, insulin glargine
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients
To evaluate the efficacy and safety of a new treatment regimen of metformin plus sitagliptin (Janumet) followed by a long-acting basal insulin (Lantus) treatment compared to the usual treatment regimen of metformin followed by…
- Trial name
- JUBILEE (NCT01269996)
- Testing
- Janumet, Lantus, metformin, gliclazide, protaphane
- Where
- Hong Kong
- Volunteers
- 71 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes Mellitus
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Primary Objectives: The co-primary objective of this study is: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) versus lixisenatide on glycemic control as assessed by…
- Trial name
- Lixilan-O-AP (NCT03798054)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Lixisenatide (AVE0010)
- Where
- 79 sites in China, Malaysia and 2 more
- Volunteers
- 878 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01114542
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
This is a single centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over, euglycaemic clamp study in subjects with type 2 diabetes on stable insulin treatment.
- Trial name
- NCT02514850
- Testing
- Biochaperone Combo, Humalog Mix25, Humalog
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)
The purpose of this study is to assess the safety, pharmacokinetics, and pharmacodynamics of MK-1293 compared with a basal insulin (EU-Lantus™) in participants with Type 1 Diabetes.
- Trial name
- NCT02059174
- Testing
- MK-1293, EU-Lantus™, Novolog™
- Volunteers
- 76 people
- Sponsor
- Merck Sharp & Dohme LLC